Upcoming Investor Conferences: Werewolf Therapeutics Insights
Participating in Key Investor Conferences
Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company, is committed to advancing the treatment of cancer through conditionally activated therapeutics. Recently, the company announced participation in important investor conferences scheduled for May, showcasing their groundbreaking efforts in the biopharmaceutical realm.
The Citizens Life Sciences Conference 2025
On May 8, 2025, Werewolf Therapeutics will take the stage at the Citizens Life Sciences Conference, held at the New York Hilton Midtown. The management team will engage in a fireside chat, presenting an opportunity to share their insights and developments with investors eager to learn more about the company.
Details of the Conference
The conference promises to be a significant event for Werewolf, as it aims to outline their newest therapies and share the company’s vision for the future. Attending conferences like this helps to strengthen their connections within the industry and engage potential investors in meaningful discussions.
Bank of America Securities 2025 Health Care Conference
Shortly thereafter, on May 14, 2025, Werewolf Therapeutics will also participate in the Bank of America Securities Health Care Conference at The Encore Hotel in Las Vegas, where they will again be involved in a fireside chat at 3:15 PM PT.
Engagement with Investors
These conferences are crucial for Werewolf as they continue to foster connections within the investment community. By discussing their advancements, such as their pioneering therapies designed to engage and stimulate the immune system, they highlight their unique position in the biopharmaceutical landscape.
Live Webcast and Conferences Archives
For those unable to attend the conferences, live webcasts will be made available on Werewolf's website, ensuring that all interested parties can access the discussions. Additionally, archived replays will be accessible for approximately 90 days following each conference.
About Werewolf Therapeutics
Werewolf Therapeutics stands at the forefront of biopharmaceutical innovation, focusing on developing conditionally activated therapeutics. The company's proprietary PREDATOR® platform is designed to create molecules that selectively activate the immune response in tumor environments while staying inactive in peripheral tissues. This innovative approach aims to sidestep the limitations associated with traditional immune therapies.
Clinical Advances
The company is advancing its lead clinical candidates: WTX-124 and WTX-330. These therapeutics are conditionally activated Interleukin-2 and Interleukin-12 molecules, respectively, being explored for their effectiveness against solid tumors. WTX-124 is being evaluated both as a stand-alone treatment and in combination with immune checkpoint inhibitors, while WTX-330 is targeted at multiple tumor types and Non-Hodgkin Lymphoma.
Investor and Media Contact Information
As they move forward with their development programs, Werewolf Therapeutics encourages open communication with potential investors and media representatives. Stakeholders can reach out through the following contacts:
Investor Contact
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
Frequently Asked Questions
What is Werewolf Therapeutics known for?
Werewolf Therapeutics specializes in developing conditionally activated therapeutics aimed at unleashing the body's immune response to combat cancer.
When will the upcoming investor conferences take place?
The conferences will occur on May 8 and May 14, 2025.
Where can I access the live webcasts of the conferences?
Live webcasts will be available on the Werewolf Therapeutics website during the conferences.
What are WTX-124 and WTX-330?
WTX-124 and WTX-330 are the company's lead drug candidates designed to activate the immune system against tumors selectively.
How can I contact Werewolf Therapeutics?
You can reach out to their investor relations or media contacts via the provided email addresses for inquiries.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.